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bstract. One of the fundamental immuno-
logic characteristics of systemic lupus erythematosus
(SLE) is a depressed T cell proliferative response to
various specific and nonspecific stimuli. Both intrinsic
cellular defect(s) and inhibitory influences of humoral
factors, e.g., antilymphocyte autoantibodies or immune
complexes, have been postulated to underly this func-
tional abnormality. Because patient serum can induce
SLE-like T cell dysfunction in normal cells, an extrinsic
mechanism is probably responsible, but the nature and
site of action of this humoral activity has not been
defined. This laboratory recently described a novel an-
tibody specific for activated T cells in SLE, which raised
the possibility that suppression ofT cell proliferation by
SLE serum involved antibodies directed to surface de-
terminants expressed during the process of activation.
In experiments to examine this concept further, relatively
warm-reactive antibodies to T cell blasts were found to
inhibit strongly the well-characterized T cell response to
tetanus toxoid. These antibodies were distinct from
conventional cold-reactive IgM antibodies to resting T
cells, which exhibited little inhibitory activity. Inhibition
involved noncytotoxic effects on early activation events
at the level of the responding T cell, which markedly
reduced the expression of receptors for interleukin 2.
Inhibitory effects on antigen-pulsed macrophages or on
T cells already committed to proliferate were not de-
monstrable. Anti-T blast antibodies were characteristic
of active SLE and were detected only occasionally in
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patients with inactive disease or non-SLE rheumatic
disorders. Although the exact antigenic specificity was
not identified, considerable evidence was obtained against
the presence of antibodies to Ia and certain other surface
determinants of functional relevance.
Our observations concerning the suppressive effects
of anti-T blast antibodies in SLE serum on the T cell
response to tetanus toxoid should provide new insight
into mechanisms of in vivo T cell dysfunction in this
and other immunologic disorders.
Introduction
Many immune system functional abnormalities are recognized
in systemic lupus erythematosus (SLE),' including defective T
cell proliferative response to various specific and nonspecific
stimuli (1-4); impaired natural killer (5, 6), antibody-dependent
(7, 8) and T cell-mediated (9, 10) cytotoxicity; failure of
suppression in multiple systems (11-15); increased numbers
of spontaneously activated B (13, 16-18) and T (19, 20) cells;
and decreased pokeweed mitogen-driven Ig production (13,
18). Certain evidence suggests that such functional abnormalities
do not reflect an intrinsic defect(s) in lymphocytes or other
cells, although this important issue has not been clarified fully.
First, lymphocyte dysfunction usually is most evident in
patients with active SLE and resolves during periods of disease
remission. Second, many of these functional abnormalities can
be reproduced in normal lymphocytes through effects of SLE
serum or plasma. Finally, most investigators have either failed
to demonstrate an intrinsic cellular defect or do not exclude
participation of in vivo humoral effects, e.g., surface receptor
modulation (21), which carry over to in vitro experiments.
1. Abbreviations used in this paper: 02m., 2 microglobulin; BRBC,
bovine erythrocyte; C, complement; CH5o, total hemolytic complement
activity; CLL, chronic lymphocytic leukemia; FITC, fluorescein iso-
thiocyanate; [3H]TdR, [3H]thymidine; IL-l, interleukin-l; IL-2, inter-
leukin-2; PHA, phytohemagglutinin; PBMC, peripheral blood mono-
nuclear cell; RA, rheumatoid arthritis; SLE, systemic lupus erythema-
tosus.
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The available data strongly suggest that antilymphocyte
antibodies contribute to certain types of abnormal lymphocyte
function in SLE (reviewed in reference 22). The mechanisms
by which antibody/lymphocyte interactions result in cellular
dysfunction are not well understood, however. Uncertainty
persists about the Ig class of the relevant antilymphocyte
antibodies, and the requirement of antibodies for complement
(C) fixation and cell lysis to exert their functional effects
(23-26). In addition, several careful studies have failed to
demonstrate an association between C-dependent lymphocy-
totoxic antibody activity and decreased T cell proliferation in
different systems despite clear evidence for potent inhibitory
activity in SLE serum (21, 27). Action of immune complexes
or IgG antilymphocyte antibodies, which are relatively non-
cytotoxic in conventional complement-dependent assays (28),
usually are invoked to explain such discrepancies.
Recently, this and other laboratories have described anti-
bodies directed to T cell activation antigens in SLE (29-31).
The existence of such antibodies raises the possibility of an
alternate mechanism for suppressive effects of SLE serum on
T cell function, i.e., interference with activation events per se
by antibodies directed to surface determinants expressed during
the process of activation. To examine this concept further, a
series of experiments was performed to clarify the role of
different types of antilymphocyte antibodies in inhibition of
the well-characterized T cell proliferative response to the
soluble protein antigen, tetanus toxoid.
Methods
Patients and serum. Peripheral blood was obtained from 20 patients
with SLE, 20 patients with rheumatoid arthritis (RA), 20 patients with
miscellaneous rheumatic diseases (polymyositis, 3; scleroderma, 4;
psoriatic arthritis, 3; osteoarthritis, 5; Reiter's syndrome, 2; and sar-
coidosis, Sjogren's syndrome, and gout, I each), and 10 normal
subjects. Patients with SLE met the revised diagnostic criteria of the
American Rheumatism Association (32) and were unselected except
for exclusion of those with prior transfusions or pregnancies. After
separation from whole blood, serum was aliquoted and stored at
-700C. Each serum aliquot was heated at 560C for 1 h immediately
before use. SLE disease activity was assessed as described previously
(33). A classification of active SLE was assigned if the patient exhibited
one or more of the following clinical manifestations: arthralgia or
arthritis, serositis, rash, oral ulcers, glomerulonephritis, pneumonitis,
or central nervous system dysfunction that could not be attributed to
causes other than SLE. Correlative serologic indices, which were not
used to determine disease activity status, included total hemolytic
complement activity (CH~o) and anti-double-stranded DNA detected
by a Crithidea luciliae immunofluorescent assay.
Lymphocyte culture. Normal human peripheral blood mononuclear
cells (PBMCs) were separated from heparinized venous blood by Ficoll-
Hypaque flotation. After being washed, cells were cultured in volumes
of 200 at a density of 106 cells/ml in RPMI 1640 medium
(University of North Carolina Cancer Center, Chapel Hill, NC) con-
taining 2 mM glutamine, antibiotics, and 10% normal human AB
serum (optimum concentration) in round-bottom tissue culture plates
(Costar, Data Packaging, Cambridge, MA) in a humid 5% C02, 95%
air incubator. Phytohemagglutinin (PHA; Burroughs Wellcome Co.,
Research Triangle Park, NC) was used at a final concentration of I
ug/ml, tetanus toxoid (Sate Biological Laboratories, Boston, MA) at
6.0 Ag/ml. Apparent proliferation was assessed by the addition of 1
;tCi [3H1thymidine ([3H]TdR) (ICN Pharmaceuticals, Inc., Irvine, CA)
per well. 18 h later, radioactivity of cells from triplicate cultures was
counted by liquid scintillation techniques. Maximum [3H]TdR incor-
poration occurred after 3 d of culture for PHA and after 5 d of culture
for tetanus toxoid. To obtain more activated T cells for use in
absorption experiments or as targets for assay of antilymphocyte
antibody activity in disease sera, PBMCs were cultured as above in
tissue culture flasks (Falcon Labware, Div. Becton, Dickinson, & Co.,
Oxnard, CA). At the time of maximum blastogenesis (day 3 for PHA
and day 5 for tetanus toxoid) cells were harvested, washed twice, and
suspended at a density of 2 X 106/ml of medium for cytotoxicity
assays, or .2 X 107/ml for absorption experiments.
To determine inhibitory activity of patient sera on mitogen- or
antigen-stimulated lymphocyte proliferation, cells were cultured in a
mixture of 5% disease serum, or Ig fractions thereof, and 5% standard
normal AB serum to minimize variability. A final concentration of 5%
was chosen for test sera because this was at or near the plateau for
inhibition observed with 7.5 or 10%. Percentage inhibition was calculated
as peak incorporated counts per minute in cultures containing test
serum divided by incorporated counts per minute in parallel cultures
containing 10% standard normal AB serum. Each SLE serum was
examined against tetanus toxoid- or PHA-stimulated PBMCs from
three normal donors, which exhibited high proliferative responses to
tetanus toxoid and PHA, i.e., -15,000-50,000 and -25,000-75,000
incorporated cpm/well, respectively. Background counts per minute in
cultures not containing antigen or mitogen were < 1,000. Variation in
the degree of inhibition of proliferation with cells from different donors
was comparable (±27%) to the precision of separate assays performed
at different times with the same SLE serum/PBMC donor combinations,
i.e., ±25% of the mean throughout the range of inhibition values
observed. There was no relationship between the degree of inhibition
seen with a given SLE serum and the magnitude of the proliferative
response induced in different PBMC donors. Therefore, inhibition data
shown in Results represent experiments performed with cells from the
same normal donor, which further reduced day-to-day experimental
variability and optimized serum-serum comparisons of inhibitory
activity. Percentage inhibition relative to control with sera from 10
normal subjects was negligible: 13±10% for tetanus toxoid-induced
proliferation, and 8±11% for PHA-induced proliferation. For certain
statistical analyses, limits for significant inhibition were established
from these data as >2 SD above the mean values for the normal sera,
i.e., >33% for tetanus toxoid-containing cultures and >30% for PHA-
containing cultures.
In certain experiments, plastic adherent peripheral mononuclear
cells were pulsed with tetanus toxoid antigen before recombination
with T cells according to the technique of Geha et al. (34). In brief,
plastic adherent macrophages (>85% esterase+) were harvested with a
rubber policeman, resuspended at a density of 1 X 105 cells/ml in
medium containing 6.0 Ag/ml tetanus toxoid and either normal AB
serum or SLE serum, and incubated for 18 h in 95% air, 5% CO2 at
370C. The antigen-pulsed macrophages were then washed three times
with RPMI 1640, recombined with 2 X I0W T cells (<1% esterase+),
purified by passage over nylon wool columns, and cultured in the
usual fashion for 5 d with or without added SLE serum.
Cell fractionation. T cells were obtained as the nonadherent pop-
ulation after passage of PBMCs over nylon wool columns (Fenwall
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Laboratories, Berkeley, CA) according to the technique of Julius et al.
(35). Nylon wool adherent cells, containing enriched numbers of B
cells and monocytes, were recovered by wringing the nylon wool at
cold temperatures. The B cells were further purified to be relatively
free of monocytes by collection as the nonadherent population after a
2-h incubation in plastic Petri dishes. Monocytes were isolated directly
from PBMCs by adherence to plastic. A variety of markers was used
to assess the purity of these enriched cell populations: esterase staining
of monocytes (36), and indirect immunofluorescence or complement-
dependent cytotoxic reactivity with monoclonal antibodies to Ia, IgM,
and pan T determinants.
Special immunological reagents. Monoclonal antibodies included
the following: L243 (anti-DR framework, American Type Culture
Collection, Rockville, MD); anti-Tac (a generous gift from Dr. T.
Waldmann, National Institutes of Health, Bethesda, MD); Leu-l,
Leu-8, Leu-10, anti-g% microglobulin (anti-#2m; Becton-Dickinson &
Co., Sunnyvale, CA); OKT3, OKT4, OKT8, OKT 1 (Ortho Diagnostics
Raritan, NJ); 5E9 (antibody to transferrin receptor, a generous gift
from Dr. B. Haynes (Duke University, Durham, NC); AAl (anti-T
blast, a generous gift from Dr. N. Chiorazzi, Rockefeller University,
New York); and fluorescein isothiocyanate (FITC)-conjugated F(ab%2
goat anti-human IgM and FITC-rabbit anti-mouse IgG (Cappel Lab-
oratories, Cochranville, PA). Chicken and rabbit anti-human Ia anti-
bodies were gifts of Dr. N. Bernard (University of North Carolina,
Chapel Hill, NC). Tetanus immune globulin was purchased from
Cutter Laboratories, Inc. (Berkeley, CA). Purified human interleukin-
2 (IL-2; ENI lot 1608-13) was purchased from Electro-Nucleonics, Inc.
(Silver Spring, MD).
Preparation ofserum Igfractions. IgG (7S) and IgM (19S) frastions
were obtained from serum by sucrose density gradient ultracentrifuigation
using acid buffers (glycine-Ha, pH 3.0) as described previously (37).
For certain experiments, IgG was prepared by DEAE cellulose chro-
matography and IgM was purified by affinity chromatography using
anti-IgM-Sepharose 4B. After concentration of fractions to approxi-
mately the original serum volume, IgG and IgM concentrations were
determined by nephelometry.
Microcytotoxicity. C-dependent microcytotoxicity was performed
as previously described (28) with the use of modifications for detecting
either cold- or warm-reactive antibodies. For detection of cold-reactive
antibodies, 2 X 103 cells in a volume of 1 uld were mixed with 1 ul of
serum, or Ig fraction thereof, in Terasaki plates (Falcon Labware) for
I h at 150C. 5 ;&I of prescreened rabbit C (Pel-Freez Biologicals,
Rogers, AR) was then added for an additional 3-h incubation at 15°C.
Both stages were performed at 25°C for warm-reactive antibody assay.
Cells were then stained with 5% eosin, fixed in 40% formalin, and
examined by inverted phase-contrast microscopy. Cytotoxicity was
expressed as the percentage of nonviable cells. For mitogen or antigen-
stimulated T cell targets, anti-T blast cytotoxicity was calculated as a
percentage of total cells. In comparisons ofantilymphocyte cytotoxicity
and capacity of SLE serum to inhibit the tetanus toxoid response,
PBMCs from the same normal donor were used in both assays. The
percentage dead cells in assays with C alone or with C plus normal
human AB serum was <10%. Sera giving >10% cell killing were scored
as positive for lymphocytotoxic antibody.
Monoclonal antibody rosettes and rosette inhibition. The monoclonal
antibody rosette assay was performed according to Stocker et al. (38),
by means of goat anti-mouse IgG-coated bovine erythrocytes (BRBCs;
Biological Products, Winston-Salem, NC) as indicator cells. 200 MAl of
50% packed BRBCs and 100 Ml of affinity-purified goat anti-mouse
IgG (800 jig/ml, a gift from Dr. R. Eisenberg, University of North
Carolina) were mixed and followed by dropwise addition of 200 Ml of
2.5 mM chromic chloride (39). After incubation of the reaction
mixture for 5 min at room temperature, anti-IgG-coated BRBCs were
washed thoroughly and resuspended to 1% in RPMI 1640 supplemented
with 10% fetal calf serum (Hyclone, Logan, UT). 50 ul of a suspension
of target lymphocytes (2.5 X 10) was incubated with 50 ul of appropriate
dilutions of monoclonal antibody for 30 min at 4VC. After washing
was done, target cells were suspended in RPMI 1640 containing 10%
fetal calf serum to a final density of 4 X 106/ml, combined with an
equal volume (usually 50 Ml) of a 1% suspension of anti-mouse IgG-
coated BRBCs, and centrifuged for 10 min at 200 g in small tubes
(Fisher Scientific Co., Pittsburgh, PA). After incubation in ice water
for 30 min, the BRBC/lymphocyte mixture was gently resuspended,
stained with Giemsa, and applied to glass microscope slides for
microscopy to determine percentage rosette forming cells. At least 200
cells were counted in each assay. Cells used as targets included chronic
lymphocytic leukemia (CLL) cells; normal resting T cells purified
through nylon wool columns; and T cell blasts activated by PHA. The
following antibodies were studied in this assay: QKT3, OKT8, Leu-l,
Leu-8 (anti-pan T); OKT4 (helper/inducer); OKT8 (suppressor/cyto-
toxic); L243 (anti-DR framework); Leu-l0 (anti-DC/DS framework);
anti-human #2>; and 5E9, anti-Tac, and AAI (antibodies to activation
neoantigens).
Antibodies in SLE sera to surface determinants recognized by the
above monoclonal antibodies were sought in experiments to inhibit
monoclonal antibody rosette formation. Target lymphocytes (1 X 106)
were preincubated with 100 Ml of SLE or normal serum for 1 h at 4VC
with frequent agitation. After pelleting and aspiration of serum, the
cells were resuspended in the highest dilution of monoclonal antibody,
giving near-maximal rosette formation, and rosettes were prepared and
enumerated as described above. Inhibition was calculated as follows:
percentage inhibition = [(a - b)/b] X 100, where a is the percentage
rosettes with normal serum preincubation and b is the percentage
rosettes with SLE serum preincubation.
The major surface antigen(s) on T cells with which IgM antilym-
phocyte antibodies in SLE sera react can be modulated, i.e., exhibit
decreased fluorescence intensity for SLE IgM staining (Yamada, A.,
M. Shaw, and J. B. Winfield, submitted for publication). This occurs
spontaneously after brief incubations in medium at 370C and is
accelerated by SLE serum. Therefore, monoclonal antibody rosette
inhibition also was examined in experiments where the target cells
were preincubated with SLE serum at 370C for 2 h before rosette
assay.
Indirect immunofluorescence and flow cytometry. 1gM and IgG
antibody binding to T cells in SLE serum was assessed by indirect
immunofluorescence at 4VC using FITC-conjugated rabbit F(ab')2
antibodies to human M- or -y-chains as the second coat. Appropriate
dilutions of mouse monoclonal antibodies and FITC-goat F(ab')2 anti-
mouse IgG were used to determine known surface antigens. After they
were stained, cells were kept at 4VC and either examined immediately
or fixed with paraformaldehyde. Fluorescence intensity and percentage
positive cells were determined by flow microfluorometry using an
Epics V instrument (Coulter Electronics Inc., Hialeah, FL) equipped
with argon laser (488 nm), MDADS and EASY 1 computers, and
appropriate software. Laser power, photomultiplier tube amplification,
and gain settings were calibrated with fluorospheres (Coulter Electronics
Inc.), and kept constant throughout the experimental run on a given
lymphocyte preparation. In some experiments, attempts were made to
block or modulate known determinants with SLE serum before staining
with mouse monoclonal antibodies.
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Absorption and elution techniques. SLE sera or Ig fractions were
exhaustively absorbed at 4VC (200 ul vol per 1 X 107 cells, repeated
twice). Cell types used for absorption included resting nylon wool
peripheral T cells; 3-d PHA- and 5-d tetanus toxoid-stimulated T
blasts; and T and B cell lines (HSB and 2080, respectively; obtained
from University of North Carolina Cancer Center Culture Facility).
Completeness of absorption was confirmed by absence of C-dependent
cytotoxicity against the absorbing cell type. To obtain eluates, 5 X 10'
PHA-activated T cells were incubated with 500 Ml SLE serum at 4VC
for I h. After they were washed three times with cold buffer, the cells
were suspended in medium and incubated for I h at 370C.
Statistical analysis. Statistical analyses of data were performed by
Dr. Julio Singer (Biometrics Consulting Laboratory, University of
North Carolina Department of Biostatistics). Because certain assump-
tions for the Chi-square test were not met, e.g., cell size <5, the two-
tail Fisher's exact test was used to examine the association of antilym-
phocyte antibody activity with capacity of SLE serum to inhibit the
tetanus toxoid response. Pearson correlations also were computed in
order to determine this relationship.
Results
In initial experiments, serum from patients with SLE or other
rheumatic diseases was added on day 0 to normal human
PBMCs cultured in the presence of tetanus toxoid or PHA.
Sera from 11/20 unselected patients with SLE inhibited the
optimum proliferative response of normal T cells to tetanus
toxoid, as assessed by incorporation of [3H]TdR on day 5 of
culture (Figs. 1 and 2). Most sera from patients with rheumatoid
arthritis and a variety of other non-SLE rheumatic diseases
were inactive in this regard.
Inhibition of the tetanus toxoid was not antigen specific,
and it involved a saturable, noncytotoxic mechanism. Thus,
nine sera also inhibited T cell proliferation induced by diph-
theria toxoid to a degree comparable to that observed with
tetanus toxoid (62±30 and 65±20%, respectively). Reduction
in incorporated (3H]TdR reflected a true inhibition of prolif-
eration rather than a shift in the time course of maximum
response, as shown in kinetic experiments with six SLE sera.
A plateau occurred with final serum concentrations between 5
and 10%; e.g., in a typical experiment, inhibition with 5, 7.5,
and 10% added SLE serum was 65, 79, and 81%, respectively.
Cell viability was not reduced in cultures containing SLE
serum; i.e., >95% of cells excluded trypan blue in inhibited
and control cultures throughout the first 5 d of culture, with
a decline to 85-90% on day 6. Cell counts were the same in
SLE serum and control cultures from day 0-day 4 but fell to
25-50% of control by day 6. The titer of inhibitory activity
was <1:16.
Inhibition of PHA-stimulated T cell proliferation was
observed with 8/20 sera but usually was low (mean = 28%),
even though suboptimal concentrations of PHA were used.
The capacity of sera to inhibit the tetanus toxoid response was
not significantly associated with inhibition of the PHA response
(P = 0.09 by two-tail Fisher's exact test), primarily because of














Figure 1. Kinetics of inhibition of tetanus toxoid-induced T cell
proliferation by SLE serum. Cultures contained 5% heat-inactivated
SLE serum (o) or standard normal AB serum (x) added on day 0.
Data points represent mean [3H]TdR incorporation from triplicate
cultures in a representative experiment. Background counts per min-
ute were <1,000, and were not subtracted.
the former but not the latter. Increasing the number of sera
studied in this fashion to 28 did not strengthen this association
statistically. However comparisons of inhibition of the tetanus
toxoid and PHA responses by regression analysis revealed a
significant relationship (Pearson correlation coefficient = 0.56,
loo- "Figure 2. Inhibition of teta-
nus toxoid-induced T cell
°80- proliferation by SLE and
other rheumatic disease
o sera. Percentage inhibition
.s 8 60- of peak [3H]TdR incorpo-
ration measured on day 5
relative to parallel cultures
a, 40 - * containing a standard nor-
Oat8 D mal AB serum was most
:e 20- ° marked for active SLE sera
(.). Sera from patients with
AM=
inactive SLE (o), rheuma-
SLE RA MISC toid arthritis (A&), and mis-
cellaneous (MISC) rheu-
Disease Sera Added To Culture matic diseases (0) generally
lacked inhibitory activity. Inhibition by 10 normal sera was negligible
(mean±SD = 13±10%). All sera were present continuously from the
outset of culture.
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P = 0.01). This suggested that a common inhibitory effect did
indeed exist for SLE serum in both the antigen- and mitogen-
induced T cell responses. Modest inhibition of the PHA
response was seen with RA and certain miscellaneous rheumatic
disease sera, a finding that contrasted with the uniform failure
of such sera to inhibit tetanus toxoid-stimulated cultures.
These data suggest that SLE serum exerts a quantitatively
more potent effect on antigen-induced T cell responses and
argue against a major role for nonspecific influences on cellular
proliferation in general.
Relationship to SLE disease activity and therapy. Thirteen
of the 20 patients with SLE were classified on clinical grounds
as having active disease at the time of study. This group had
lower CH" levels (mean±SD = 19±15 U/ml; normal, 25-40
U/ml) and were relatively more lymphopenic (694±360 lym-
phocytes/mm3) than the seven inactive patients (CH50 = 29±9
U/ml; absolute lymphocytes, 1,108±241/mm3). Inhibition of
the tetanus toxoid response was higher for active SLE sera
(mean±SD = 64±30%) than for inactive SLE sera (10±13%).
Such a marked difference in the degree of inhibition was not
observed in PHA-stimulated cultures (inhibition by active SLE
sera, 34±29%; inhibition by inactive SLE sera, 16±19%).
13 of the patients were being treated with prednisone.
Although the average daily dose in 8/11 patients whose sera
inhibited the tetanus toxoid responses was higher 20±17
mg/d) than in the 5/9 patient sera that did not (11 10 mg/d),
there was little difference in inhibitory activity for sera from
corticosteroid-treated and untreated patients (mean inhibition
= 52±30 and 42±40%, respectively). Inhibition of the PHA
response also was similar in the treated (32±29%) and untreated
(20±22%) patients.
Inhibition ofthe tetanus toxoid and PHA responses by SLE
serum Ig. The activity in SLE serum that inhibited the tetanus
toxoid response was recovered in both IgM and IgG fractions
obtained by sucrose density gradient ultracentrifugation using
pH 3.5 buffers. In certain sera, both IgM and IgG inhibited
the tetanus toxoid response; on a molar basis, however, IgG
was less inhibitory than IgM. For example, with two such sera,
the final concentrations of IgM giving 50% inhibition were 11
and 40 ,g/ml, whereas 270 and 260 ,u/ml of IgG were required.
In other patients, very low concentrations of IgM were inhib-
itory, but IgG was inactive (Table I). To demonstrate further
the Ig class, IgM was purified from a pool of six SLE sera by
affinity chromatography. At a final concentration in culture of
20 Ag/ml, this highly purified IgM gave 50% inhibition of the
response. Inhibition was not observed with IgG or IgM fractions
from normal sera, or with Ig from patients with inactive SLE
who lacked inhibitory activity in whole serum.
The recovery of inhibitory activity in acid pH gradient
fractions from SLE sera was of special interest because this
suggested that antibodies, rather than immune complexes,
were involved. The failure of heat-aggregated normal IgG
(final concentration, 200 ,g/ml) to inhibit provided additional
evidence in this regard. To exclude further an inhibitory effect
of immune complexes in SLE serum or Ig fractions, six sera
Table L Inhibition of Tetanus Toxoid-induced
T Cell Proliferation by SLE Serum IgM:
Relationship to Anti-T Blast Antibody Activity
Anti-T blast antibody
Inhibition of
Ig conc [3H]TdR IF staining
(pg/ml)* incorp (%)* C-cytotox (%)§ (%MY
IgM IgG IgM IgG IgM IgG IgM IgG
Su(SLE) 9 162 64 11 20 <10 58 <1
He(SLE) 8 190 40 5 30 <10 35 <1
Mc(SLE) 5 163 39 19 20 <10 18 <1
SLE pool 20 <2 50 70 80 <1
Normal 33 410 0 8 <10 <10 <1 <1
* Final concentration (conc) per culture of IgM and IgG fractions.
IgM was isolated from SLE patients Su, He, and Mc, and from nor-
mal serum as the 19S fraction by sucrose density gradient ultracen-
trifugation using pH 3.5 buffers. IgM from a pool of six SLE sera was
purified by affinity chromatography. IgG was prepared free of con-
taminating IgM by ammonium precipitation followed by DEAE cel-
lulose chromatography.
t Calculated as percentage inhibition of [3H]TdR incorporation (in-
corp) by IgM or IgG serum fractions on day 5 relative to control cul-
tures containing 10% standard normal AB serum.
§ Determined with IgM or IgG serum fractions in parallel two-stage
microcytotoxicity assays performed at 250C. IgG concentrations in
cytotoxicity (cytotox) and immunofluorescence assays were 20-fold
higher than those shown; values represent percentage dead cells.
11 Determined with whole serum by indirect immunofluorescence (IF)
using FITC-F(abl anti-IgM or FITC-F(ab%) anti-IgG reagents. Val-
ues represent percentage stained cells.
and the affinity purified IgM were ultracentrifuged at 105,000
g for 2 h at 4VC. After ultracentrifugation, which removes Clq
binding activity (15), the top, middle, and bottom thirds of
each sample were compared in tetanus toxoid inhibition
assays. As shown in Table II, this treatment had little effect
on inhibitory activity. In other experiments, 19S IgM fractions
that inhibited the response (Table I) were examined for immune
complex-like activity in a fluid-phase Clq binding assay (kindly
performed by Dr. Greg Bisecker (Hahnemann University,
Philadelphia, PA). Immune complexes were not detected (sen-
sitivity, 5 jLg/ml).
Increased serum Ig per se, or anti-tetanus toxoid antibody
in the SLE sera did not contribute to inhibition of the tetanus
toxoid response. Mean serum Ig levels in the SLE patients
(IgG, 14.7±11.8 mg/ml; IgM, 1.8±3.3 mg/ml), while higher
than in the 10 normal subjects (IgG, 11.9±2.6 mg/ml; IgM,
1.3±0.4 mg/ml), were similar to the levels in RA sera (IgG,
18.3±6.5 mg/ml; IgM, 1.8± 1.0 mg/ml), which were not inhib-
itory. Furthermore, there was no relationship between Ig
concentration and inhibitory activity in individual SLE sera.
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Table II. Effect of Ultracentrifiugation
on Inhibitory Activity in SLE Serum
Inhibition of ['HJTdR incorporation after ultracentrifugation
(% relative to control)
Patient Upper 1/3 Middle 1/3 Bottom 1/3
Ta 90 92 99
Ch 97 99 99
Heg 98 98 99
Mi 99 98 96
Mc 77 83 86
Gi 53 42 68
SLE IgM 48 50 68
Samples were ultracentrifuged for 2 h at 40C. The upper, middle,
and bottom thirds were then compared in a tetanus toxoid inhibition
assay. SLE IgM was purified by affinity chromatography from a pool













Inhibition of the Tetanus Toxoi
ated Figure 3. Association of
anti-T cell antibody with
capacity to inhibit the teta-
nus toxoid T cell prolifera-
tive response. SLE sera that
significantly inhibited the
tetanus toxoid response (o)
exhibited increased anti-
body activity against both
resting T cells and T cell
blasts as determined in
-u---- C-dependent cytotoxicity
NEG assays. Sera that did not in-
Reponse hibit the tetanus toxoid re-
sponse (e) generally lacked such antibodies. Inhibitory activity was
more strongly associated with warm-reactive anti-T blast antibody (P
= 0.006) than with cold-reactive antibody to resting T cells (P
= 0.03). Significant inhibition was defined as >2 SD above the mean
value for 10 normal sera. POS, positive; NEG, negative.
Anti-tetanus toxoid antibody titers as determined by hemag-
glutination were actually lower in the SLE sera than in the
RA or normal sera (data not shown). Finally, human tetanus
immune globulin that contained anti-tetanus toxoid antibody
in a titer of >1:1,000 per milligram IgO did not inhibit the
response when added to cultures in a final concentration of
420 Azg/ml.
Association of inhibition with antilymphocyte antibody.
Conventional cold-reactive antilymphocyte antibodies were
demonstrable in 8/11 (73%) of SLE sera that inhibited tetanus
toxoid T cell proliferation, as determined in two-stage micro-
cytotoxicity assays performed at 15'C using unstimulated
PBMCs as targets. Conversely, 6/9 sera (67%) that did not
inhibit the response lacked such antibodies, suggesting that at
least one inhibitory component in SLE serum might be an
antilymphocyte antibody. Also supporting this possibility was
the relative absence of lymphocytotoxic antibodies in the non-
SLE sera which, in general, failed to inhibit the tetanus toxoid
response (normal sera, 0/10 positive; RA sera, 5/20 positive;
and miscellaneous rheumatic disease sera, 3/20 positive).
To define the mononuclear cell specificity of antibodies in
SLE serum that might be involved in inhibition of tetanus
toxoid-stimulated T cell proliferation, correlative studies were
performed using well-characterized PBMC subpopulations and
activated T cells as targets. In these experiments, the thermal
amplitude of the cytotoxic antibodies was assessed by cold
(15'C) and warm (250C) assay temperatures. As shown in
Figs. 3 and 4, a particularly strong relationship was evident
for relatively warm-reactive antibodies directed toward T cell
blasts (P = 0.006 by two-tail Fishers exact test; Pearson cor-
relation coefficient = 0.67, P = 0.0012). In such 250C assays,
the great majority of SLE sera (17/20) were noncytotoxic for
unstimulated T cells. However, when cytotoxicity for unstim-
ulated T cells was examined at 150C, a significant, albeit
weaker, association between inhibition of the tetanus toxoid
response and cold-reactive antibody activity was apparent
(Fisher's exact test, P = 0.03). Low levels (<15% killing) of
warm-reactive antibodies were detected in only 2/20 RA sera
and 3/20 miscellaneous rheumatic disease sera.
The antibodies to activated T cells in sera that inhibited
the tetanus toxoid response were predominantly of the IgM
class. IgM fractions obtained under immune complex-disso-
ciating conditions from certain strongly inhibitory sera con-
tained anti-T blast cytotoxic activity, whereas highly purified
IgG from the same sera did not (Table I). Conversely, IgM
fractions from three patients that lacked the capacity to inhibit
the response also lacked anti-T blast antibody. Indirect im-
munofluorescent staining of T cell blasts in sera inhibiting the
tetanus toxoid response was higher for IgM (mean±SD posi-
tive cells = 43±30%) than for IgG (percentage positive cells
= 4±9%), although staining in the range of -25% was seen
with several sera. Affinity purified IgM from a pool of six SLE
sera lysed 70% of activated T cells in the presence of comple-
ment when assayed at a concentration of 400 Ag/ml, and
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cultures at a final concentration of 20 ,ug/ml. Finally, ultracen-
trifugation of serum or serum IgM fractions reduced neither
IgM staining of T cell blasts (data not shown) nor inhibition
of tetanus toxoid blastogenesis.
Cytotoxic antibodies to non-T cells obtained as nylon
wool-adherent cells (>85% Ia+, 40-70% SIgM+, 15-40%
esterase+, and 5-15% OKT3+) were not associated with
inhibition of the tetanus toxoid response (P = 0.17). Antibodies
to plastic adherent cells, consisting of 80-90% esterase+ mono-
cytes, were demonstrable in only 2/20 SLE sera. In other
experiments, SLE sera were examined for their capacity to
develop reverse hemolytic plaques by the use of tetanus toxoid
and PHA blast cells as targets (37). Only 6/20 sera developed
T-plaque-forming cells, and this was not related to inhibition
of the tetanus toxoid response.
Additional evidence to suggest a role for anti-T cell blast
antibodies in inhibition of the tetanus toxoid response was
obtained in a series of absorption experiments. Four SLE sera
with anti-T blast antibodies (cytotoxicity, 50, 55, 80, and 90%)
were exhaustively absorbed with nylon wool-enriched resting
peripheral T cells, or with tetanus toxoid- or PHA-stimulated
T cell blasts, and examined for residual inhibition of the
tetanus toxoid response. T cell blasts of either type completely
removed the inhibitory activity (Fig. 5). Absorption with
unstimulated T cells was uniformly ineffective in this regard.
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Figure S. Reduction in the capacity to inhibit the tetanus toxoid
response after absorption of SLE sera with T cell blasts. Sera from
four patients with SLE were exhaustively absorbed with either resting
T cells (A) or tetanus toxoid-stimulated T cell blasts harvested on day
5 (o). Unabsorbed (e) and absorbed sera were then compared for
inhibitory activity in tetanus toxoid proliferation assays using PBMCs
from the same donor used in the absorption experiments. T blast
absorptions eliminated cytotoxic antibodies to both resting and acti-
vated T cells. Resting T cell absorptions removed only antibodies
cytotoxic for resting T cells.
both warm-reactive antibodies cytotoxic for T cell blasts and
cold-reactive antibodies to unstimulated T cells. In the converse
experiment, absorption with unstimulated T cells decreased
warm-reactive cytotoxicity for T cell blasts <10% relative to
unabsorbed serum in three patients, and 44% (from 80 to 45%
killing) in the fourth. In other experiments, a T cell line (HSB)
partially absorbed inhibitory activity from three of four sera,
but to a lesser degree than did the peripheral blood T cell
blasts. An Ia+ B cell line (2080) removed >95% of inhibitory
activity from one serum but not from three others (<5, 10,
and 35% reduction relative to unabsorbed serum). These data
suggested that inhibition ofthe tetanus toxoid response involved
antibody to surface determinants expressed either de novo on
activated T cells or in greater density relative to unstimulated
cells.
To clarify further the question of specificity for activation
neoantigen(s) vs. resting T cell antigen(s), which were relatively
increased in density on activated cells, additional absorptions
(six instead of two) with unstimulated T cells were performed
(Table III). This procedure reduced the starting IgM concen-
tration by 10%, e.g., from 2.0 to 1.8 mg/ml. As shown,
neither warm-reactive cytotoxicity for T cell blasts nor the
capacity to inhibit the tetanus toxoid response was eliminated,
although a partial reduction in T blast cytotoxicity was observed
with one serum.
To demonstrate directly that antibodies to activated T cells
inhibited the tetanus toxoid response, eluates were obtained
by 37°C incubation of T blasts used for absorption. Each of
three eluates inhibited the response: Mi eluate, 71%; Ta eluate,
41%; and He eluate, 35%. Inhibitory activity in the eluates
was associated with recovery of warm-reactive cytotoxic anti-
body against T cell blasts: Mi eluate, 80% killing; and Ta
eluate and He eluates, 30% killing. Inhibition was not observed
with control eluates.
Kinetics and mechanism of inhibition. As shown in Table
IV, the kinetics of inhibition of the tetanus toxoid response
were similar to those observed with L243, a monoclonal anti-
DR framework antibody (40); i.e., considerably greater inhi-
bition occurred when serum was added at the initiation of
culture than at later times. Antibody to Tac, the IL-2 receptor
(41), was inhibitory when added as late as day 3. This suggested
that interference with early events in the tetanus toxoid
response was operant. To examine this issue, peripheral blood
plastic adherent cells were incubated for 18 h at 37°C with
tetanus toxoid in the presence of either SLE serum or normal
AB serum. After thorough washing, the antigen-pulsed adherent
cells were recombined with fresh purified T cells. Incorporated
[3H]TdR on day 5 was compared with that seen with unfrac-
tionated PBMCs exposed to antigen and cultured with SLE
serum throughout, or in reconstituted cultures to which SLE
serum was not added until the antigen-pulsed cells were
recombined with T cells. Four SLE sera were studied in this
fashion. Serum present only during the 18 h that adherent
cells were pulsed with tetanus toxoid did not inhibit T cell
proliferation in reconstituted cultures (mean inhibition±SD
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Table III. Failure ofRepeated Absorptions* ofSLE Serum with Unstimulated T Cells or Erythrocytes
to Remove Tetanus Toxoid Response Inhibitory Activity or Cytotoxic Antibody to T Cell Blasts
Inhibition of [3HJTdR incorp (%)t T cell blast cytotoxicity (% dead cells)§
SLE Resting T T cell Resting T T cell
serum Unabs RBC abs cell abs blast abs Unabs RBC abs cell abs blast abs
Hg 42 50 39 11 70 70 60 40
Su 52 52 55 9 60 60 20 <10
Sm 82 82 86 4 >95 >95 >95 <10
Unabs, unabsorbed; abs, absorbed. * 200 ,d of SLE serum was absorbed six times, instead of the usual two times, with 1 X 107 unstimulated T
cells or an equivalent volume of packed erythrocytes (RBC), per absorption, and then examined for capacity to inhibit the 5-d tetanus toxoid
response and for residual cytotoxicity for T cell blasts. Data obtained after absorptions with T cell blasts (two times with 1 X 107 cells per
absorption) are shown for comparison. t % Inhibition of [3H]TdR incorporation was calculated from triplicate values based upon a mean
counts per minute of 21,736 (stimulation index = 23.6) in control cultures containing 10% normal AB serum. § Determined in parallel two-
stage C-dependent cytotoxicity assays performed at 250C. Residual cytotoxicity at 150C for unstimulated T cells after resting T cell absorptions
was <10% in each case.
= 21±20%). Exposure to SLE serum after tetanus toxoid-
pulsed adherent cells and T cells were recombined resulted in
inhibition (46±50%) nearly as marked as that seen when
PBMCs were cultured with antigen and SLE serum beginning
at day 0 (64±34%). These data suggested that SLE serum was
acting upon relatively early activation events at the T cell level
rather than upon antigen processing by accessory cells.
To elucidate further the mechanism of inhibition, the
proportion of cells expressing IL-2 receptors (Tac) and the
relative surface membrane density of Tac on T cells during
the tetanus toxoid response was determined by indirect im-
munofluorescence and flow microfluorometry procedures (Fig.
Table IV. Kinetics ofInhibition of the Tetanus Toxoid and
PHA Proliferative Responses by SLE Serum and
Various Monoclonal Antibodies to Cell Surface Determinants
Inhibition of [3H]TdR incorporation (% of control)*
Day SLE serum Anti-Ia Anti-Tac
added
to culture Tet tox PHA Tet tox PHA Tet tox PHA
0 74±13 40±4 78 12 60 <10
1 27±12 29±12 56 <10 61 <10
2 25±12 33±15 <10 <10 55 <10
3 31±1 28±12 18 <10 52 <10
4 10±7 20 <10
5 <10 15 <10
* Values for SLE serum represent the mean±SD inhibition for sera
from four different patients selected for inhibitory activity in both the
tetanus toxoid (tet tox) and PHA responses. The highest dilution of
the monoclonal anti-Ia (L243) and anti-Tac antibodies that gave
maximum inhibition when added on day 0 was used. Control cul-
tures contained 10% normal AB serum.
6). In control cultures, the percentage of Tac+ cells increased
progressively in association with a shift toward staining of
higher fluorescence intensity. In SLE serum-inhibited cultures,
the expression of Tac was markedly attenuated. Similar results
were obtained when Tac+ cells were enumerated by monoclonal
antibody rosetting (data not shown). In related experiments,
the addition of exogenous IL-2 on day 0 or day 1 dramatically
enhanced maximum day 5 [3H]TdR incorporation in control
cultures but only partially restored the response in SLE serum-
containing cultures (Fig. 7). Collectively, these data provide
further evidence that the early phase inhibitory effect of SLE
serum on peak proliferation involved interference with the
initial expression of IL-2 receptors, and, as a consequence,
with responsiveness to IL-2.
Specificity of antilymphocyte antibodies. Because others
have reported antibodies to Ia in SLE sera (30) with potent
suppressive effects on T cell proliferative responses involving
recognition of Ia determinants (42), autoantibodies to Ia
appeared to be particularly attractive candidates to explain the
early phase inhibition of the tetanus toxoid response by SLE
serum. Several approaches were used in efforts to demonstrate
such antibodies. First, pre-incubation of CLL cells (-65%
Ia+) or T cell blasts (-20% Ia+) at 40C with the 20 SLE sera
before addition of an appropriate dilution of monoclonal anti-
DR framework antibody L243 did not inhibit rosette formation
between the anti-Ia-coated target cells and goat anti-mouse
IgG-coated ox erythrocytes. Mean inhibition in the presence
of SLE serum was only 3±5%, well within the range observed
with a panel of 10 normal sera, 2±5%. Similar data were
obtained with Leu-10, a monoclonal antibody with DS/DC
framework specificity. In contrast, both rabbit and chicken
anti-Ia antibodies inhibited rosette formation by >95%. As it
is possible that the putative anti-Ia antibody in SLE serum
must be directed at the identical epitope with which L243
reacts in order to inhibit rosette formation, attempts were
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Figure 6. SLE serum inhibits the expression of IL-2 receptors. The
proportion of T cells expressing IL-2 receptors was determined in
tetanus toxoid-stimulated PBMC cultures containing normal AB
serum or SLE serum by indirect immunofluorescence and flow mi-
crofluometry using anti-Tac. SLE serum markedly reduced the per-
centage Tac+ cells throughout the 5 d of culture. Overall surface
membrane density of IL-2 receptors, as assessed by relative fluores-
cence intensity of Tac staining, also was reduced by SLE serum.
Number of cells is along the ordinate; relative fluorescence intensity
of Tac staining is along the abscissa.
made to modulate Ia antigen from the target cells by a 2-h
371C pre-incubation with SLE serum. CLL cells treated in
this way showed no decrease in L243 rosettes: 41±9 vs.
39±15% in normal human serum control assays. In other
experiments, the presence of anti-Ia antibodies was sought in
an assay based on inhibition of C-mediated cytotoxicity using
chicken anti-Ia antibody, which does not fix C. Pre-incubation
of nylon wool-purified non-T cells (85% Ia+) with chicken
anti-Ia completely prevented killing by L243 but had no effect
on cytotoxicity by the SLE sera.
In studies to be reported in detail separately (42a), antibodies
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Figure 7. Decreased responsiveness of SLE serum inhibited tetanus
toxoid cultures to exogenous IL-2. Purified human IL-2, 12.8 (e) or
25.6 (A) half-maximal [3H]TdR units per culture, was added at time
0 or on days 1-3 to cultures containing either standard normal AB
serum (-) or SLE serum ---) present continuously from time
0. Incorporated [3H]TdR was determined on day 5. Data represent
percentage [3H]TdR uptake relative to that observed in AB serum
control cultures (o). IL-2 partially restored the T cell proliferative
response of '80% inhibited SLE serum-containing cultures. Marked
enhancement above control was seen in AB serum-containing cul-
tures, especially when IL-2 was added at time 0 or day 1.
these approaches. Surface determinants studied on resting or
PHA-activated T cell targets included: T3, TI 1, Leu-l, Leu-8
(pan-T); T4, T8 (T subset); #2m; and Tac, 5E9, and AAl
(other activation antigens). Significant rosette inhibition, either
directly at 4VC or after modulation of IgM antilymphocyte
antibody-reactive target cell antigen at 370C, was seen only
for f2m (13/20 sera positive; inhibition, 17-58%). Next, relative
fluorescence intensity of lymphocyte staining by FITC-conju-
gated monoclonal antibodies was assessed by flow microfluo-
rometry after modulation of SLE antibody-reactive antigen.
Modulation typically reduced both the fluorescence intensity
of SLE antilymphocyte antibody IgM staining and the per-
centage of T cells scored as IgM+ (60-95% IgM+ -4 15-35%
IgM+). Except for #2m, however, the relative fluorescence
intensity for the known surface antigens was not altered (data
not shown).
Discussion
Several lines of evidence indicate that relatively warm-reactive
antibodies to activated T cells in SLE exert potent inhibitory
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effects upon antigen-induced T cell proliferation. First, inhi-
bition of the T cell response to tetanus toxoid was highly
correlated with the presence of such antibodies in serum of
patients with active disease. Inhibition was not observed with
sera from patients with inactive SLE or with non-SLE rheumatic
diseases, or with sera from normal subjects that lacked anti-T
blast antibodies. Second, both inhibitory activity and cytotoxic
antibody to T cell blasts were localized to serum 1g, including
fractions isolated by use of immune complex-dissociating
conditions. Both IgM and IgG antibodies were identified,
although the former was most active. Third, T cell blasts
absorbed completely the capacity to inhibit the tetanus toxoid
response in parallel with removal of anti-T cell antibody;
absorption with resting T cells eliminated cold-reactive cyto-
toxicity for unstimulated T cells but did not decrease inhibitory
activity or anti-T cell blast antibody. Finally, warm-reactive
cytotoxic antibody and inhibitory activity were recovered in
370C eluates from activated T cells after absorption at 4VC.
Other factors in SLE serum that potentially could inhibit
the tetanus toxoid response include immune complexes, cor-
ticosteroids (43), anti-tetanus toxoid antibody, and anti-tetanus
toxoid auto-antiidiotypic antibodies (44). Although some con-
tribution to inhibitory effects of whole serum by immune
complexes or corticosteroids is difficult to exclude entirely,
such nonantibody factors did not appear to play a significant
role. Thus, inhibitory activity could be recovered in Ig fractions
that were isolated under immune complex-dissociating condi-
tions and that did not contain demonstrable immune com-
plexes. Heat-aggregated IgG did not inhibit. In addition, inhib-
itory activity was not removed by ultracentrifugation. There
was no relationship between therapy and inhibition of the
response, and several of the SLE sera that were most inhibitory
were from patients with active disease who were receiving no
therapy. Similarly, it is unlikely that inhibition was due to an
anti-tetanus toxoid antibody or auto-antiidiotypic antibodies.
Tetanus toxoid antibody titers in the SLE patients were not
higher than those in normal subjects or patients with non-SLE
disorders that did not inhibit. Antibody inhibiting the response
could be absorbed completely with PHA-induced T cell blasts,
which would not be expected to express the tetanus toxoid
idiotype to any significant degree. Tetanus immune globulin
had no effect on the response.
Antibodies to T cell blasts have been described previously
in RA (45) and SLE (31). In SLE, IgG antibodies react with
soluble products of activated T cells. No association of this
interesting type of antibody with inhibition of the T cell
tetanus toxoid response was apparent, however. In RA, IgM
antibodies exhibit increased cytotoxicity for T blasts but can
be absorbed completely with unstimulated cells. The absorption
data in SLE suggest that anti-T blast antibodies are directed
to a neoantigen(s) not expressed on resting T cells, although it
remains possible that the preferential activity with T blasts
reflects increased surface membrane expression of a determinant
also present on unstimulated T cells, but at very low density.
If such were the case, cold-reactive IgM antibodies to resting
T cells might also contribute to inhibition of the tetanus toxoid
response, as has been suggested previously (46). Further studies
will be required to clarify the relationships among these
interesting anti-T cell antibody systems.
The kinetics of inhibition of the T cell response to tetanus
toxoid by SLE serum closely paralleled those of anti-Ia. This
suggested that anti-T cell antibodies in SLE interfere with the
induction of T cell activation, or with early events in the
activation phase that take place during the first 24-48 h of
culture (47, 48). Proliferation occurring later involves com-
mitted cells no longer requiring IL-2 or antigen (48, 49, 50)
and was not inhibited by SLE serum. An effect at the level of
the antigen-presenting cell, which must internally process
antigen and recycle it to the cell surface for association with
Ia molecules as the critical first signal (50), is unlikely. Thus,
[3H]TdR incorporation by T cells stimulated by macrophages
pulsed with tetanus toxoid in the presence of SLE serum was
not reduced, a finding consistent with the absence of demon-
strable antimonocyte antibodies in most sera. Despite consid-
erable effort, antibodies to Ia of the type described previously
in sera from patients with active SLE (30, 42) could not be
detected. SLE sera did not inhibit monoclonal anti-DR and
anti-DS/DC framework rosette formation, whereas rabbit and
chicken anti-Ia reagents were quite effective in this regard.
Absorption with an Ia+ B cell line failed to decrease inhibitory
activity on the tetanus toxoid response in three of four SLE
sera. Nevertheless, the fact that antigen may be presented in
the context of class II molecules other than DR (51), and the
limited data obtained thus far against the presence of putative
Ia specificities, certainly leave open the possibility of Ia blockade.
The failure of many SLE sera to inhibit blastogenesis induced
by suboptimal concentrations of PHA argues against any
interference with delivery of the second signal for T cell
activation, i.e., interleukin-l (IL-1) production by macrophages
and IL-l/IL-l receptor interaction.
The action of antibody on T cells responding to inductive
stimuli is more consistent with the present d~tta. Greater
inhibition of the tetanus toxoid response relative to the PHA
response could derive simply from a smaller responding cell
precursor frequency in the former, as has been shown in other
systems (52), even though suboptimal concentrations of PHA
and optimal concentrations of tetanus toxoid were used in the
cultures. Thus, a common inhibitory influence might exist in
both the nonspecific mitogen response and the specific antigenic
response, with greater activity on the latter because the number
of responding cells is smaller. Perhaps favoring such a common
mechanism was the similar efficiency of tetanus toxoid- and
PHA-induced T cell blasts to absorb antibody inhibiting the
tetanus toxoid response. Furthermore, regression analysis re-
vealed a significant association between inhibition of the two
responses by the SLE sera.
It is interesting that the early phase inhibitory activity of
SLE anti-T cell blast antibodies reduced the initial expression
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of IL-2 receptors (Tac+ cells) and markedly attenuated the
proliferative response of cultures to additional exogenous
IL-2. (Although not approached in this study, the production
of IL-2 was probably reduced as well.) The inhibition kinetics
here are consistent with interaction of SLE antibody with T
cell receptors for antigen or class II molecules (53-55), or with
IL-2 receptors. Other potential mechanisms requiring further
investigation include antibodies to isotypic or clonotypic de-
terminants of the T cell antigen receptor; antibodies to IL-2,
although this is unlikely; and antibodies that deliver an off
signal analogous to that shown with OKT1 1 (56).
Our studies concerning the specificity of anti-T blast
antibodies provided no evidence for blockade or modulation
of the T3, T4, or Tac molecules but were indirect and subject
to alternate interpretations. Crucial to the clarification of this
issue are experiments to characterize directly the reactive
antigen(s) by immunoprecipitation or immunoblotting proce-
dures. Preliminary Western blot data from our laboratory
show that SLE antibodies that inhibit the tetanus toxoid
response detect several surface membrane molecules on acti-
vated T cells that are not apparent on resting gels (unpublished
observations). The most prominent of these have approximate
molecular weights of 56,000, 51,000 and 32,000. Others recently
have identified SLE antibody-reactive glycoproteins by im-
munoprecipitation with molecular weights of 42,000 and 66,000
on PHA activated peripheral T cells and an adult T cell
leukemia line (57). These proteins appear to be identical with
the IL-2 receptor, a finding obviously relevant to the present
functional observations.
Despite uncertainty about the exact specificity of the
antibodies involved, the present observations provide insight
into mechanisms underlying certain aspects of immunologic
dysfunction in SLE. First, a depressed proliferative response
of T cells to soluble antigens and a variety of other specific
and nonspecific stimuli is characteristic of cells isolated from
patients with this disorder (1-4). Our data indicate that such
abnormal function can be reproduced, at least with respect to
the tetanus toxoid system, in normal lymphocytes through
effects of a novel type of antibody to activated T cells. Since
most previous investigations have considered only those anti-
bodies that are reactive with resting T cells, the present findings
provide an explanation for the failure to define a clear rela-
tionship between abnormal cell function and antilymphocyte
antibodies to resting T cells (21, 27).
Because antilymphocyte antibodies in SLE can mediate
cell killing in the absence of complement (58, 59) or modulate
the expression of surface receptors at physiologic temperatures
(21) with consequent alteration in lymphocyte function, lym-
phocyte/antilymphocyte antibody interactions of the type de-
scribed here probably occur in vivo. Such in vivo autoantibody
effects on circulating lymphocytes in SLE could carry over to
in vitro experiments even in the absence of persisting antibody
and thereby influence putatively intrinsic lymphocyte functional
properties. Relevant examples of this include defective pro-
duction of IL-2 (60) and decreased proliferative response to
tetanus toxoid of T cells from patients with SLE (2). Of even
greater interest is the idea that auto-antibodies to T cells in
this disorder are fundamentally important in pathogenesis, as
suggested by their association with lymphopenia (61), with a
variety of T cell functional abnormalities, and with active
disease. It will be especially challenging in future studies to
determine whether antibodies with the functional effects on T
cell activation demonstrated herein reflect an exaggerated
homeostatic regulatory mechanism in response to ongoing
autoimmune reactions, or play a causal role in the underlying
pathogenesis of SLE and related disorders.
Acknowledaments
We give special appreciation to the late Dr. Henry G. Kunkel for
certain pivotal ideas that stimulated this investigation. The technical
assistance of Melody Shaw and Rekha Shah is gratefully acknowledged.
We also thank Dr. Philip Cohen and Dr. Robert Eisenberg for advice
and criticism, and Cathy Miller-Wells and Aretha Jones for typing the
manuscript.
This research was supported in part by National Institutes of
Health grant RO-I AM 30863, the University of North Carolina
Multipurpose Arthritis Center, and an Arthritis Foundation Clinical
Research Center grant.
References
1. Rosenthal, C. J., and E. C. Franklin. 1975. Depression of
cellular-mediated immunity in systemic lupus erythematosus. Arthritis
Rheum. 18:2077-217.
2. Gottlieb, A. B., R. G. Lahita, N. Chiorazzi, and H. G. Kunkel.
1979. Immune function in systemic lupus erythematosus. Impairment
of in vitro T cell proliferation and in vivo antibody response to
exogenous antigen. J. Clin. Invest. 63:885-892.
3. Sakane, T., A. D. Steinberg, and I. Green. 1978. Failure of
autologous mixed lymphocyte reactions between T and non-T cells in
patients with systemic lupus erythematosus. Proc. Nati. Acad. Sci.
USA. 75:3464-3468.
4. Horwitz, D. A., M. A. Garrett, and A. H. Craig. 1977. Serum
effects on mitogenic reactivity in subjects with systemic lupus erythe-
matosus, rheumatoid arthritis, and scleroderma. Technical considera-
tions and lack of correlation with anti-lymphocyte antibodies. Clin.
Exp. Immunol. 27:100-1 10.
5. Karsh, J., G. Dorval, and C. K. Osterland. 1981. Natural
cytotoxicity in rheumatoid arthritis and systemic lupus erythematosus.
Clin. Immunol. Immunopathol. 19:437 446.
6. Silverman, S. L., and E. S. Cathcort. 1980. Natural killing in
systemic lupus erythematosus: inhibitory effects of serum. Clin. Im-
munopathol. 17:219-226.
7. Scheinberg, M. A., and E. S. Cathcart. 1976. Antibody-dependent
direct cytotoxicity of human lymphocytes. I. Studies on peripheral
blood lymphocytes and sera of patients with systemic lupus erythe-
matosus. Clin. Exp. Immunol. 24:317-322.
8. Schneider, J., W. Chin, G. J. Friou, S. M. Cooper, B. Harding,
R. L. Hill, and F. P. Quismorio. 1975. Reduced antibody-dependent
cell-mediated cytotoxicity in systemic lupus erythematosus. Clin. Exp.
Immunol. 20:187-192.
9. Charpentier, B., C. Carnaud, and J. F. Bach. 1979. Selective
1958 A. Yamada and J. B. Winfield
depression of xenogeneic cell-mediated lympholysis in systemic lupus
erythematosus. J. Clin. Invest. 64:351-360.
10. Tsokos, G. C., and J. E. Balow. 1981. Cytotoxic responses to
alloantigens in systemic lupus erythematosus. J. Clin. Immunol. 1:208-
216.
11. Bresnihan, B., and H. E. Jasin. 1977. Suppressor function of
peripheral blood mononuclear cells in normal individuals and in
patients with systemic lupus erythematosus. J. Clin. Invest. 59:106-
116.
12. Fauci, A. S., A. D. Steinberg, B. F. Haynes, and G. Whalen.
1978. Immunoregulatory aberrations in systemic lupus erythematosus.
J. Immunol. 121:1473-1479.
13. Sakane, T., A. D. Steinberg, and I. Green. 1978. Studies of
immune functions of patients with systemic lupus erythematosus. I.
Dysfunction of suppressor T-cell activity related to impaired generation
of, rather than response to, suppressor cells. Arthritis Rheum. 21:657-
664.
14. Sakane, T., H. Kotani, S. Takada, Y. Murakawa, and Y. Ueda.
1983. A defect in the suppressor circuits among OKT4+ cell populations
in patients with systemic lupus erythematosus occurs independently of
a defect in the OKT8+ suppressor T cell function. J. Immunol.
131:753-761.
15. Morimoto, C., E. L. Reinherz, J. A. Distaso, A. D. Steinberg,
and S. F. Schlossman. 1984. Relationship between systemic lupus
erythematosus T cell subsets, anti-T cell antibodies, and T cell functions.
J. Clin. Invest. 73:689-700.
16. Jasin, H. E., and M. Ziff. 1975. Immunoglobulin synthesis by
peripheral blood cells in systemic lupus erythematosus. Arthritis Rheum.
18:219-228.
17. Budman, D. R., E. B. Merchant, A. D. Steinberg, B. Doft,
M. E. Gershwin, E. Lizzio, and J. P. Reeves. 1977. Increased sponta-
neous activity of antibody-forming cells in the peripheral blood of
patients with active SLE. Arthritis Rheum. 20:829-833.
18. Ginsburg, W. W., F. D. Finkelman, and P. E. Lipsky. 1979.
Circulating and pokeweed mitogen-induced immunoglobulin-secreting
cells in systemic lupus erythematosus. Clin. Exp. Immunol. 35:76-88.
19. Yu, D. T. Y., R. J. Winchester, S. M. Fu, A. Gibofsky, H. S.
Ko, and H. G. Kunkel. 1980. Peripheral blood Ia-positive T cells.
Increases in certain diseases and after immunization. J. Exp. Med.
151:91-100.
20. Cohen, P. L., D. A. Litvin, and J. B. Winfield. 1982. Association
between endogenously activated T cells and immunoglobulin-secreting
B cells in patients with active systemic lupus erythematosus. Arthritis
Rheum. 25:168-173.
21. Wernet, P., and H. G. Kunkel. 1973. Antibodies to a specific
surface antigen on T cells in human sera inhibiting mixed leukocyte
culture reactions. J. Exp. Med. 138:1021-1026.
22. Winfield, J. B. 1984. Anti-lymphocyte antibodies in SLE.
Specificity and relationship to abnormal cellular function. In Systemic
Lupus Erythematosus. R. Lahita, editor. John Wiley & Sons, New
York. In press.
23. Sakane, T., A. D. Steinberg, J. P. Reeves, and I. Green. 1979.
Studies of immune functions of patients with systemic lupus erythe-
matosus. Complement-dependent immunoglobulin M anti-thymus-
derived cell antibodies preferentially inactivate suppressor cells. J. Clin.
Invest. 63:954-965.
24. Sagawa, A., and N. I. Abdou. 1979. Suppressor-cell antibody
in systemic lupus erythematosus. Possible mechanism for suppressor-
cell dysfunction. J Clin. Invest. 63:536-539.
25. Glinski, W., M. E. Gershwin, and A. D. Steinberg. 1976.
Fractionation of cells on a discontinuous Ficoll gradient. Study of
subpopulations of human T cells using anti-T cell antibodies from
patients with systemic lupus erythematosus. J. Clin. Invest. 57:604-
614.
26. Sakane, T., A. D. Steinberg, J. P. Reeves, and I. Green. 1979.
Studies of immune functions of patients with systemic lupus erythe-
matosus. T cell subsets and antibodies to T cell subsets. J. Clin. Invest.
64:1260-1269.
27. Horwitz, D. A., and J. B. Cousar. 1975. A relationship between
impaired cellular immunity, humoral suppression of lymphocytes and
severity of systemic lupus erythematosus. Am. J. Med. 58:829-835.
28. Winfield, J. B., R. J. Winchester, P. Wernet, S. M. Fu, and
H. G. Kunkel. 1975. Nature of cold-reactive antibodies to lymphocyte
surface determinants in systemic lupus erythematosus. Arthritis Rheum.
18:1-8.
29. Williams, R. C., Jr., A. D. Bankhurst, and J. D. Montano.
1976. IgG anti-lymphocyte antibodies in SLE detected by '25l-protein
A. Arthritis Rheum. 19:1261-1270.
30. Okudaira, K., R. P. Searles, J. L. Ceuppens, J. S. Goodwin,
and R. C. Williams, Jr. 1982. Anti-Ia reactivity in sera from patients
with systemic lupus erythematosus. J. Clin. Invest. 69:17-24.
31. Litvin, D. A., P. L. Cohen, and J. B. Winfield. 1983. Charac-
terization of warm-reactive IgG anti-lymphocyte antibodies in systemic
lupus erythematosus. Relative specificity for mitogen-activated T cells
and their soluble products. J. Immunol. 130:181-186.
32. Tan, E. M., A. S. Cohen, J. F. Fries, A. T. Masi, D. J.
McShane, N. F. Rothfield, J. G. Schaller, N. Talal, and R. F.
Winchester. 1982. The 1982 revised criteria for the classification of
systemic lupus erythematosus. Arthritis Rheum. 25:1271-1277.
33. Winfield, J. B., C. M. Brunner, J. S. Davis IV, and W. M.
O'Brien. 1972. Assessment of disease activity in systemic lupus erythe-
matosus (SLE). Arthritis Rheum. 15:462. (Abstr.)
34. Geha, R. S., H. Milgrom, M. Broff, S. Alpert, S. Martin, and
E. J. Yunis. 1979. Effect of anti-HLA antisera on macrophage-T-cell
interaction. Proc. NatL. Acad. Sci. USA. 76:4038-4041.
35. Julius, M. H., E. Simpson, and L. A. Herzenberg. 1973. A
rapid method for isolation of functional thymus-derived murine lym-
phocytes. Eur. J. Immunol. 3:645-649.
36. Nardiello, S., P. Pizzella, M. Russo, and B. Galanti. 1982.
Esterase staining of monocytes in suspensions of Ficoll-Hypaque
isolated mononucler cells. J. Immunol. Methods. 52:111-114.
37. Winfield, J. B., R. J. Winchester, P. Wernet, and H. G. Kunkel.
1975. Specific concentrations of anti-lymphocyte antibodies in the
serum cryoprecipitates of patients with systemic lupus erythematosus.
Clin. Exp. Immunol. 19:399-406.
38. Stocker, J. W., G. Garotta, B. Hausmann, M. Trucco, and R.
Ceppellini. 1979. Separation of human cells bearing HLA-DR antigens
using a monoclonal antibody rosetting method. Tissue Antigens 13:212-
222.
39. Goding, J. W. 1976. The chromic chloride method of coupling
antigens to erythrocytes: definition of some important parameters. J.
Immunol. Methods. 10:61-66.
40. Lampon, L. A., and R. Levy. 1980. Two populations of Ia-like
molecules on a human B cell line. J. Immunol. 125:293-299.
41. Miyawaki, T., A. Yachie, N. Uwadana, S. Ohzeki, T. Nagaoki,
and N. Taniguchi. 1982. Functional significance ofTac antigen expressed
on activated human T lymphocytes: Tac antigen interacts with T cell
growth factor in cellular proliferation. J. Immunol. 129:2474-2478.
42. Okudaira, K., R. P. Searles, J. S. Goodwin, and R. C. Williams,
Jr. 1982. Antibodies in the sera of patients with systemic lupus
1959 Functional Effects ofAnti-T Blast Antibodies in SLE
erythematosus that block the binding of monoclonal anti-Ia to
Ia-positive targets also inhibit the autologous mixed lymphocyte re-
sponse. J. Immunol. 129:582-586.
42a. Yamada, A., M. Shaw, and J. B. Winfield. Surface antigen
specificity of anti-lymphocyte autoantibodies in systemic lupus erythe-
matosus (SLE). Arthritis Rheum. In press.
43. Hirschberg, H., T. Hirschberg, H. Nousioinen, L. R. Braether,
and E. Jaffe. 1982. The effects of corticosteroids on the antigen
presenting properties of human monocytes and endothelial cells. Clin.
Immunol. Immunopathol. 23:577-585.
44. Saxon, A., and E. Barnett. 1984. Human auto-antiidiotypes
regulating T cell-mediated reactivity to tetanus toxoid. J. Clin. Invest.
73:342-348.
45. Searles, R. P., R. P. Messner, and S. M. Hermanson. 1981.
Anti-lymphocyte antibodies in rheumatoid arthritis: increased reactivity
against activated lymphocytes. Clin. Immunol. Immunopathol. 20:246-
254.
46. Winfield, J. B., P. I. Lobo, and A. Singer. 1978. Significance
of anti-lymphocyte antibodies in systemic lupus erythematosus. Arthritis
Rheum. 21:S215-S221.
47. DeFreitas, E. C., R. W. Chesnut, H. M. Grey, and J. M.
Chiller. 1983. Macrophage-dependent activation of antigen-specific T
cells requires antigen and a soluble monokine. J. Immunol. 131:23-29.
48. Lipkowitz, S., W. C. Greene, A. L. Rubin, A. Novogrodsky,
and K. H. Stenzel. 1984. Expression of receptors for interleukin-2:
role in the commitment of T lymphocytes to proliferate. J. Immunol.
132:31-37.
49. Gunther, G. R., J. L. Wang, and G. M. Edelman. 1974. The
kinetics of cellular commitment during stimulation of lymphocytes by
lectins. J. Cell Biol. 62:366-377.
50. Unanue, E. R., D. I. Beller, C. Y. Lu, and P. M. Allen. 1984.
Antigen presentation: comments on its regulation and mechanism. J.
Immunol. 132:1-5.
51. Qvigstad, E., and E. Thorsby. 1983. Class-II HLA restriction
of antigen-specific human T-lymphocyte clones. Evidence of restriction
elements on both DR and MT molecules. Scand. J. Immunol. 18:299-
306.
52. Lane, H. C., G. Whalen, and A. S. Fauci. 1983. Antigen-
induced human T cell help. Precursor frequency, radiation sensitivity,
and allogeneic effects. J. Clin. Invest. 72:636-647.
53. Biddison, W. E., P. E. Rao, M. A. Talle, G. Goldstein, and S.
Shaw. 1983. Possible involvement of the T4 molecule in T cell
recognition of class II HLA antigens: evidence from studies of prolif-
erative responses to SB antigens. J. Immunol. 131:152-157.
54. Chang, T. W., P. C. Kung, S. P. Gingras, and G. Goldstein.
1981. Does OKT3 monoclonal antibody react with an antigen-recog-
nization structure on human T cells? Proc. NatW. Acad. Sci. USA.
78:1805-1808.
55. Reinherz, E. L., R. E. Hussey, and S. F. Schlossman. 1980. A
monoclonal antibody blocking human T cell function. Eur. J. Immunol.
10:758-762.
56. Palacios, R., and 0. Martinez-Maza. 1982. Is the E receptor
on human T lymphocyte a "negative signal" receptor? J. Immunol.
129:2479-2485.
57. Kagami, M., T. Koike, H. Tomioka, and S. Yoshida. 1984.
IgG anti-lymphocyte autoantibody specific for an adult T cell leukemia
cell line and activated lymphocytes in sera from patients with SLE.
Arthritis Rheum. 27:S83. (Abstr.)
58. Kumagai, S., A. D. Steinberg, and I. Green. 1981. Antibodies
to T cells in patients with systemic lupus erythematosus can induce
antibody-dependent cell-mediated cytotoxicity against human T cells.
J. Clin. Invest. 67:605-614.
59. Okudaira, K., R. P. Searles, K. Tanimoto, Y. Horiuchi, and
R. C. Williams, Jr. 1982. T lymphocyte interaction with immunoglob-
ulin G antibody in systemic lupus erythematosus. J. Clin. Invest.
69:1026-1038.
60. Linker-Israeli, M., A. L. Bakke, R. C. Kitridou, S. Gendler, S.
Gillis, and D. A. Horwitz. 1983. Defective production of interleukin 1
and interleukin 2 in patients with systemic lupus erythematosus (SLE).
J. Immunol. 130:2651-2655.
61. Winfield, J. B., R. J. Winchester, and H. G. Kunkel. 1975.
Association of cold-reactive antilymphocyte antibodies with lympho-
penia in systemic lupus erythematosus. Arthritis Rheum. 18:587-594.
1960 A. Yamada and J. B. Winfield
